Welcome to our dedicated page for INTUITIVE SURGICAL SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical, Inc. (ISRG) is the issuer in a Rule 144 notice filed for planned sales of its common stock by officer Fredrik Carl Widman. The notice covers the potential sale of 2,178 shares of Intuitive Surgical common stock, to be sold through Morgan Stanley Smith Barney LLC on or after September 15, 2026, in connection with an exercise of stock options for cash. The filing lists an aggregate market value of $823,153.32 for the securities covered.
INTUITIVE SURGICAL INC (ISRG) executive Mark Brosius, EVP & Chief Manufacturing and Supply Chain, reported selling a total of 48 shares of common stock in open market or private transactions on September 10 and 11, 2026, under a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
INTUITIVE SURGICAL INC (ISRG) reported that executive vice president and chief manufacturing and supply chain officer Mark Brosius sold a total of 69 shares of common stock in two transactions. On September 8, 2026 he sold 46 shares at $361.23 per share, and on September 9, 2026 he sold 23 shares at $350.20 per share. Both sales were made in open market or private transactions pursuant to a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
INTUITIVE SURGICAL INC (ISRG) received a Rule 144 notice covering a planned sale of its common stock by officer Mark Preston Brosius. The notice relates to 694 shares of common stock held in an account at Morgan Stanley Smith Barney, with an aggregate market value of $254,489.80 as of September 8, 2026.
The shares derive from performance stock units awarded by the issuer, with a grant date of February 28, 2026. The notice also lists prior Rule 10b5-1 plan sales of ISRG common stock by Brosius over the past three months in small increments.
INTUITIVE SURGICAL INC (ISRG) reported that executive vice president and Chief Manufacturing and Supply Chain officer Mark Brosius sold a total of 154 shares of common stock in two open-market transactions on August 20 and 21, 2026, at prices of $396.37 and $375.57 per share. Both sales were made pursuant to a pre-arranged Trading Plan that complies with SEC Rule 10b5-1 and is disclosed as expiring on February 14, 2027.
INTUITIVE SURGICAL INC (ISRG) executive Mark Brosius, EVP & Chief Manufacturing and Supply Chain, reported three small open-market sales of common stock, each for 77 shares, on August 17, 18, and 19, 2026, at per-share prices of $390.67, $394.00, and $394.26, respectively. All transactions were executed under a Rule 10b5-1 trading plan that the company states complies with SEC requirements and expires on February 14, 2027.
INTUITIVE SURGICAL INC director Gary S. Guthart reported an indirect sale of common stock for a trust on August 11, 2026. The trust sold 10,000 shares of common stock at a price of $400.00 per share in an open-market or private transaction. After this sale, the trust held 1,245,679 shares indirectly. Separate indirect holdings of 15,720 shares each are reported in trusts for a daughter and a son. The sale was executed under a Rule 10b5-1 trading plan expiring on June 15, 2027.
Intuitive Surgical Inc. director Amy L. Ladd reported two open-market sales of Intuitive Surgical common stock. On August 10, 2026, she sold 400 shares at $379.00 per share, and on August 11, 2026, she sold 72 shares at $393.10 per share. Both transactions were executed under a Rule 10b5-1 trading plan that expires on May 15, 2027.
Intuitive Surgical Inc. executive Gary Loeb, EVP & Chief Legal and Compliance Officer, reported selling 400 shares of common stock on August 10, 2026 at $379.00 per share. Following this sale, he directly holds 5,320 shares. The sale was executed under a Rule 10b5-1 Trading Plan that expires on January 29, 2027.